MYMX.US Mymetics Corp
- Market cap
- USD 45.00
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is MYMX.US undervalued?
Graham numberThe Graham number of Mymetics Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mymetics Corp fundamental analysis
No fundamental analysis for Mymetics Corp yet.
Mymetics Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mymetics Corp
Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, and malaria. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; and national institutes of health. The company was formerly known as ICHOR Corporation and …
Full company profileMymetics Corp financial statements
Mymetics Corp annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.40M | 3.15M | 1.25M | 202K | 75.0K | 111K | 35.0K | 3.00K | 3.00K | 6.00K |
| Gross Profit | 834K | 1.42M | 252K | -615K | -1.14M | -859K | -1.02M | -972K | -1.44M | -1.10M |
| Operating Income | -667K | -393K | -3.41M | -1.51M | -1.52M | -1.38M | -1.57M | -1.65M | -1.75M | -2.44M |
| EBITDA | -631K | -347K | -3.36M | -1.47M | -1.49M | -1.47M | -1.43M | -1.96M | -1.99M | - |
| Net Income | -3.26M | -3.01M | -5.96M | -4.11M | -4.17M | -4.19M | -4.16M | -4.73M | -4.81M | -11.6M |
| EPS | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | - |
| Balance Sheet | ||||||||||
| Total Assets | 11.0M | 11.7M | 8.34M | 8.04M | 7.81M | 7.68M | 8.10M | 7.63M | 7.32M | - |
| Total Liabilities | 41.1M | 44.6M | 47.1M | 50.9M | 54.8M | 58.9M | 63.4M | 67.7M | 72.2M | - |
| Shareholders' Equity | -30.1M | -32.9M | -38.8M | -42.9M | -47.0M | -51.2M | -55.4M | -60.1M | -64.9M | - |
| Cash & Short-term Investments | 1.61M | 2.38M | 1.39M | 1.18M | 479K | 683K | 1.08M | 571K | 313K | - |
| Total Debt | 40.4M | 43.2M | 45.8M | 50.4M | 54.8M | 58.7M | 63.4M | 67.7M | 72.0M | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 2.97M | 730K | -987K | -2.45M | -2.31M | -972K | -1.70M | -1.70M | -1.69M | -1.74M |
| Capital Expenditure | 45.0K | 20.0K | 3.00K | 37.0K | 36.0K | 36.0K | 14.0K | 10.0K | 2.00K | 0.00 |
| Free Cash Flow | 2.92M | 710K | -990K | -2.49M | -2.31M | -1.01M | -1.71M | -1.71M | -1.69M | -1.74M |
| Ratios | ||||||||||
| ROA | -29.6% | -25.7% | -71.5% | -51.1% | -53.4% | -54.5% | -51.4% | -62.0% | -65.6% | - |
| Net Profit Margin | -135.7% | -95.4% | -476.0% | -2,035.6% | -5,562.7% | -3,772.1% | -11,880.0% | -157,666.7% | -160,166.7% | -192,783.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Mymetics Corp dividends
Mymetics Corp has not paid dividends in the last 10 fiscal years.
Last stock split: 1:2000 on Dec 29, 2023.
Who owns Mymetics Corp
- Insiders 0.12%
- Institutions 0.00%
- Public & others 99.89%
- Shares outstanding 152K
- Free float 73.6K
Mymetics Corp company profile
- Company name
- Mymetics Corp
- Ticker
- MYMX.US
- Exchange
- USA Stocks
- Listed since
- Mar 30, 1995
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- ROUTE DE LA CORNICHE 4, Epalinges, Switzerland, 1066
- Phone
- 41 21 566 5772
- Website
- mymetics.com
About Mymetics Corp
Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, and malaria. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; and national institutes of health. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.
Mymetics Corp management
2- Mr. Ronald KempersCEO, COO, President & CFO · born 1968
- Mr. Mario Amacker Ph.D.Head of Quality & Manufacturing